BAYER TO ACQUIRE STEIGERWALD ARZNEIMITTELWERK (ENGLISH)

     (The following press release from Bayer was received by e-mail. It was not 
confirmed by the sender.) 
Dear Newsletter Subscriber, 
The following news item has been released: 
Strategic move to strengthen Consumer Care business:
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Transaction includes Iberogast® and Laif® brands 
Leverkusen, Germany, May 16, 2013 - Bayer signed an agreement Thursday to
acquire 100% of the shares of Steigerwald Arzneimittelwerk GmbH, Darmstadt,
Germany, a privately held pharmaceutical company specializing in
pharmacy-only herbal medicines. Steigerwald’s product portfolio includes
Iberogast® for the treatment of functional gastrointestinal disorders and
Laif® for the treatment of mild to moderate depression. Financial details
have not been disclosed. The transaction is subject to fulfillment of the
usual conditions, including antitrust clearance, and is expected to close
at the beginning of July 2013. 
"This transaction is further evidence of our commitment to augment organic
growth with strategic bolt-on acquisitions. It will allow us to provide
consumers with an even broader range of self-care options," said Dr. Marijn
Dekkers, CEO of Bayer AG. "This acquisition broadens our product offering
for the treatment of gastrointestinal disorders and gives us the
opportunity to enhance our presence in Germany, the fast-growing regions of
East-Central Europe, and the CIS countries." 
Klaus Möller, one of Steigerwald’s shareholders, added: "As a family-owned
business, we take great pride in what we have achieved in nurturing and
developing our brands. We believe that Bayer, with its extensive marketing,
sales, distribution and research expertise, is well positioned to take our
success to the next level." 
Steigerwald generated sales of EUR 61.3 million in 2012. The company
employs approximately 180 people and has its headquarters and manufacturing
site in Darmstadt. Bayer has committed to take over all of Steigerwald’s
employees. The Darmstadt site and the sales organization are to retain
their existing structures. 
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the fields of health
care, agriculture and high-tech materials. As an innovation company, it
sets trends in research-intensive areas. Bayer’s products and services are
designed to benefit people and improve the quality of life. At the same
time, the Group aims to create value through innovation, growth and high
earning power. Bayer is committed to the principles of sustainable
development and acts as a socially and ethically responsible corporate
citizen. In fiscal 2012, the Group employed 110,500 people and had sales of
EUR 39.8 billion. Capital expenditures amounted to EUR 2.0 billion, R&D
expenses to EUR 3.0 billion. For more information, go to
http://www.bayer.com. 
About Steigerwald Arzneimittelwerk
Steigerwald Arzneimittelwerk GmbH, headquartered in Darmstadt, Germany,
researches, develops and manufactures high-quality herbal medicines using
the latest scientific knowledge and production technologies with the aim of
offering physicians, pharmacists and patients effective, well tolerated
treatments based on natural ingredients. The company continuously invests
large sums in clinical and pharmacological studies on the efficacy and
tolerance of its principal products. Another major focus is on explaining
the results of the extensive studies to physicians and pharmacists. 
For more information, go to http://www.bayer.com or
http://www.steigerwald.com. 
Forward-Looking Statements
This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, development or performance of the company and the estimates
given here. These factors include those discussed in Bayer’s public reports
which are available on the Bayer website at http://www.bayer.com. The
company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments. 
This press release is available here:
http://www.baynews.bayer.de/baynews/baynews.nsf/id/2013-0285-e 
Yours BayNews Editorial Team 
Bayer AG
Communications
Building W11
51368 Leverkusen, Germany 
--------------------------------------------------- 
Further news releases you can find here: http://www.press.bayer.com 
N.B. This is an automatically generated e-mail which you cannot reply to.
If you have any questions, please send us an e-mail via our contact form:
https://secure.bayer.com/bayer/contact.aspx?lang=en 
You can cancel your subscription to the BayNews-Newsletter or change your
personal settings at any time by going to
https://ssl.bayer.com/baynews/baynews.nsf/id/EN_userprofile?open 
To ensure receipt, please add pressrelease@bayer-newsletter.de to your
address book or list of trusted senders. 
--------------------------------------------------- 
© Bayer AG, 51368 Leverkusen, Germany. 
All rights reserved. The entire contents, including images, graphics,
animations etc., of this e-mail and the server http://www.bayer.com are
copyrighted. 
Board of Management: Marijn Dekkers, Chairman | Werner Baumann, Michael
König, Wolfgang Plischke, Richard Pott
Chairman of the Supervisory Board: Werner Wenning
Registered office: Leverkusen | Local Court  of Cologne, HRB 48248